⌕
Spyre Therapeutics · SYRE · Nasdaq
Tenet 43 · Weak
Compare
$93.81−5.60%At closeTenet 43 · Weak
$93.81−5.56 (−5.60%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Spyre Therapeutics (SYRE) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is SYRE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 16, 2026 · 11:22 ET
Spyre Therapeutics, Inc. (SYRE) Presents at UBS Global Biopharma Conference 2026 Transcript

Spyre Therapeutics, Inc. (SYRE) Presents at UBS Global Biopharma Conference 2026 Transcript…

SYRE −5.6% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate …

SYRE −5.6% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 19
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”). SKYLINE Part B is …

SYRE −5.6% todayRead at source ↗
● GlobeNewsWireOct 18, 2026 · 09:30 ETCOMPANY'S OWN WORDS
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology …

SYRE −5.6% todayRead at source ↗
● Seeking AlphaOct 7, 2026 · 14:18 ETEARNINGS EXPECTED BY FEB 19
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential

Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. SYRE's three monotherapy candidates—SPY001, SPY002, SPY003—show potential best-in-class efficacy for…

SYRE −5.6% todayRead at source ↗
● GlobeNewsWireOct 5, 2026 · 20:13 ETCOMPANY'S OWN WORDS
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate …

SYRE −5.6% todayRead at source ↗
● GlobeNewsWireOct 5, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate …

SYRE −5.6% todayRead at source ↗
● Defense WorldOct 4, 2026 · 09:02 ET
Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale

What happened Spyre Therapeutics, Inc. (NASDAQ: SYRE) Chief Legal Officer and Corporate Secretary Heidy King-Jones sold 28,933 shares on 2026-10-01. The Form 4 shows five sale blocks at weighted-average prices from $89.2…

SYRE −5.6% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate …

SYRE −5.6% todayRead at source ↗
● Defense WorldOct 2, 2026 · 05:41 ET
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – Should You Buy?

Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)'s stock price gapped up prior to trading on Wednesday. The stock had previously closed at $84.72, but opened at $88.64. Spyre Therapeutics shares last traded at $…

SYRE −5.6% todayRead at source ↗
● Defense WorldSep 28, 2026 · 08:15 ET
Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison

Spyre Therapeutics (NASDAQ: SYRE - Get Free Report) and Gain Therapeutics (NASDAQ: GANX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the s…

SYRE −5.6% todayRead at source ↗
● Defense WorldSep 15, 2026 · 03:26 ETEARNINGS EXPECTED BY FEB 19
California State Teachers Retirement System Buys 5,683,670 Shares of Spyre Therapeutics, Inc. $SYRE

California State Teachers Retirement System grew its stake in shares of Spyre Therapeutics, Inc. (NASDAQ: SYRE) by 9,594.0% in a recent quarter, according to its most recent Form 13F filing with the Securities and Exchan…

SYRE −5.6% todayRead at source ↗
● Defense WorldSep 14, 2026 · 04:45 ETEARNINGS EXPECTED BY FEB 19
11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Spyre Therapeutics, Inc. (NASDAQ: SYRE) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commis…

SYRE −5.6% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 14:17 ET
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

SYRE −5.6% todayRead at source ↗
● Zacks Investment ResearchSep 9, 2026 · 11:01 ET
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.…

SYRE −5.6% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 19
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p…

SYRE −5.6% todayRead at source ↗
● GlobeNewsWireSep 4, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate…

SYRE −5.6% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Spyre Therapeutics to Participate in Upcoming September Investor Conferences

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology…

SYRE −5.6% todayRead at source ↗
● Zacks Investment ResearchSep 3, 2026 · 12:36 ETEARNINGS EXPECTED BY FEB 19
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock?…

SYRE −5.6% todayRead at source ↗
● Zacks Investment ResearchAug 26, 2026 · 13:10 ET
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.…

SYRE −5.6% todayRead at source ↗
● BenzingaAug 26, 2026 · 10:46 ET
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles

Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock is trading lower on Wednesday after the company shared topline findings from the rheumatoid arthritis (RA) segment of its Phase 2 SKYWAY trial for SPY072.…

SYRE −5.6% todayRead at source ↗
● GlobeNewsWireAug 25, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 19
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)…

SYRE −5.6% todayRead at source ↗
● Zacks Investment ResearchAug 24, 2026 · 12:31 ET
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.…

SYRE −5.6% todayRead at source ↗
● Zacks Investment ResearchAug 24, 2026 · 12:31 ET
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?

Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.…

SYRE −5.6% todayRead at source ↗
● Zacks Investment ResearchAug 24, 2026 · 11:11 ET
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?

Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.…

SYRE −5.6% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 19. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just SYRE · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.